Investor Presentaiton
Daiichi-Sankyo
ENHERTU
Performance in Each Region (Japan, ASCA)
Steady increase in product sales due to market penetration and increasing launched countries/regions
Global product sales: FY2022 Q1 results 31.3 Bn JPY (YOY +18.4 Bn JPY) FY2022 forecast 128.4 Bn JPY (YOY +63.0 Bn JPY)
Japan
ASCA
Product sales: FY2022 Q1 results 2.4 Bn JPY (19 Mn USD)
FY2022 forecast 16.0 Bn JPY (123 Mn USD)
Product sales: FY2022 Q1 results 2.2 Bn JPY (17 Mn USD)
FY2022 forecast 6.3 Bn JPY (48 Mn USD)
Indication: HER2+ BC 3L, HER2+ GC 3L
Market share status
➤ HER2+ BC 3L: Maintaining No.1 new patient share
HER2+ GC 3L: Maintaining No.1 new patient share
Other progress
Classified as a preferred regimen for HER2+ BC 2L treatment in
guidelines (Jun.2022)
Indication: HER2+ BC 2L/3L
Market share status
Sales growing in Brazil, Hong Kong and Taiwan
Other progress
Launched in Taiwan (Apr. 2022)
ENHERTU®
trastuzumab deruxtecan
13View entire presentation